DexCom, Inc. reported second quarter 2026 financial results on July 30, 2026, announcing revenue of $1.308 billion, a 13% year-over-year increase. GAAP operating income rose to $318.3 million (24.3% margin), while diluted net income per share reached $0.64. The company raised its full-year 2026 revenue guidance midpoint to $5.18–$5.25 billion and increased margins for Non-GAAP Gross Profit, Operating Income, and Adjusted EBITDA. Strategic highlights included positive results from the CONNECT trial for type 2 diabetes patients not using insulin and the launch of a reimagined Stelo app experience. DexCom operates in the medical device industry, specializing in continuous glucose monitoring (CGM) systems and biosensing technology for diabetes management.

Dexcom, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected twelve directors and ratified Deloitte & Touche LLP as the independent auditor. Stockholders also approved the company's executive compensation on a non-binding advisory basis, receiving 277,111,475 votes in favor and 36,664,959 votes against.

Dexcom announced long-range financial targets during its 2026 Investor Day, projecting annual organic revenue growth of at least 10% through 2030 and 2030 non-GAAP margins for gross profit (67-69%), operating profit (29-30%), and adjusted EBITDA (36-37%). Additionally, the company's Board of Directors authorized a new share repurchase program of up to $1.0 billion, which is scheduled to conclude by June 30, 2027.

DexCom, Inc. announced its financial results for the quarter ended March 31, 2026, in a press release issued on April 30, 2026. The filing serves to formally disclose the company's quarterly operational and financial performance.

DexCom, Inc. announced that Kevin R. Sayer will return from a temporary leave of absence to resume his role as Executive Chairman effective March 2, 2026. Under a new letter agreement, Mr. Sayer will receive an annual base salary of $610,000 and a restricted stock unit grant with a fair value of $2,350,000.

DexCom, Inc. has expanded its Board of Directors to twelve members with the appointment of Albert F. (Rick) Osterloh, IV, effective immediately. Mr. Osterloh will serve on the Compensation and Technology Committees and has been awarded an initial equity grant of restricted stock units with a fair value of $500,000.